These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20549197)

  • 1. Bisphosphonate inhibits bone turnover in OPG(-/-) mice via a depressive effect on both osteoclasts and osteoblasts.
    Shoji S; Tabuchi M; Miyazawa K; Yabumoto T; Tanaka M; Kadota M; Maeda H; Goto S
    Calcif Tissue Int; 2010 Aug; 87(2):181-92. PubMed ID: 20549197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Reveromycin A on experimental tooth movement in OPG-/- mice.
    Tanaka M; Miyazawa K; Tabuchi M; Yabumoto T; Kadota M; Yoshizako M; Yamane C; Kawatani M; Osada H; Maeda H; Goto S
    J Dent Res; 2012 Aug; 91(8):771-6. PubMed ID: 22674934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
    Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
    Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice.
    Kimura M; Miyazawa K; Tabuchi M; Maeda H; Kameyama Y; Goto S
    Calcif Tissue Int; 2008 Feb; 82(2):137-47. PubMed ID: 18183447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
    Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
    Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
    Li M; Xu D
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates Reduce Smoking-Induced Osteoporotic-Like Alterations by Regulating RANKL/OPG in an Osteoblast and Osteoclast Co-Culture Model.
    Zhu S; Häussling V; Aspera-Werz RH; Chen T; Braun B; Weng W; Histing T; Nussler AK
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts.
    Enjuanes A; Ruiz-Gaspà S; Peris P; Ozalla D; Álvarez L; Combalia A; Martínez de Osaba MJ; Monegal A; Pares A; Guañabens N
    Endocrine; 2010 Feb; 37(1):180-6. PubMed ID: 20963568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
    Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
    Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption.
    Sasaki T
    Microsc Res Tech; 2003 Aug; 61(6):483-95. PubMed ID: 12879416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
    Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
    Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Rho-GEF Kalirin regulates bone mass and the function of osteoblasts and osteoclasts.
    Huang S; Eleniste PP; Wayakanon K; Mandela P; Eipper BA; Mains RE; Allen MR; Bruzzaniti A
    Bone; 2014 Mar; 60():235-45. PubMed ID: 24380811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.